

# Effect of Standard vs Intensive Blood Pressure Control on Vessel Disease

JAMA Neurology

75, 720

DOI: [10.1001/jamaneurol.2017.5153](https://doi.org/10.1001/jamaneurol.2017.5153)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Dangers of Overly Aggressive Blood Pressure Control. <i>Current Cardiology Reports</i> , 2018, 20, 108.	1.3	4
2	Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. <i>The Cochrane Library</i> , 2018, 7, CD010315.	1.5	28
3	Association Between Insulin Resistance, Plasma Leptin, and Neurocognition in Vascular Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 921-929.	1.2	13
4	Small vessel disease: mechanisms and clinical implications. <i>Lancet Neurology</i> , The, 2019, 18, 684-696.	4.9	853
5	Disrupted functional and structural connectivity within default mode network contribute to WMH-related cognitive impairment. <i>NeuroImage: Clinical</i> , 2019, 24, 102088.	1.4	44
6	Prospects for Diminishing the Impact of Nonamyloid Small-Vessel Diseases of the Brain. <i>Annual Review of Pharmacology and Toxicology</i> , 2020, 60, 437-456.	4.2	12
7	New Treatment Approaches to Modify the Course of Cerebral Small Vessel Diseases. <i>Stroke</i> , 2020, 51, 38-46.	1.0	59
8	Blood Pressure Management in Stroke. <i>Hypertension</i> , 2020, 76, 1688-1695.	1.3	17
9	Treatment of hypertension reduces cognitive decline in older adults: a systematic review and meta-analysis. <i>BMJ Open</i> , 2020, 10, e038971.	0.8	27
10	Protocol: The Lacunar Intervention Trial 2 (LACI-2). A trial of two repurposed licenced drugs to prevent progression of cerebral small vessel disease. <i>European Stroke Journal</i> , 2020, 5, 297-308.	2.7	22
11	Effect of intensive blood pressure control on the prevention of white matter hyperintensity: Systematic review and meta-analysis of randomized trials. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1968-1973.	1.0	27
12	Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. <i>The Cochrane Library</i> , 2020, 2020, CD010315.	1.5	19
13	Risk factors of white matter hyperintensities in South Asian patients with transient ischemic attack and minor stroke. <i>Neuroradiology</i> , 2020, 62, 1279-1284.	1.1	9
14	Cerebral macro- and microcirculatory blood flow dynamics in successfully treated chronic hypertensive patients with and without white matter lesions. <i>Scientific Reports</i> , 2020, 10, 9213.	1.6	9
15	Genetically determined blood pressure, antihypertensive drug classes, and risk of stroke subtypes. <i>Neurology</i> , 2020, 95, e353-e361.	1.5	60
16	Steady-state cerebral autoregulation in older adults with amnesic mild cognitive impairment: linear mixed model analysis. <i>Journal of Applied Physiology</i> , 2020, 129, 377-385.	1.2	4
17	Intracerebral Hemorrhage in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy. <i>Stroke</i> , 2021, 52, 985-993.	1.0	25
18	Individual markers of cerebral small vessel disease and domain-specific quality of life deficits. <i>Brain and Behavior</i> , 2021, 11, e02106.	1.0	3

#	ARTICLE	IF	CITATIONS
19	Gait and balance impairments in patients with subcortical vascular cognitive impairment. <i>Egyptian Journal of Neurology, Psychiatry and Neurosurgery</i> , 2021, 57, .	0.4	1
20	Associations Between White Matter Hyperintensity Burden, Cerebral Blood Flow and Transit Time in Small Vessel Disease: An Updated Meta-Analysis. <i>Frontiers in Neurology</i> , 2021, 12, 647848.	1.1	41
21	Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of cognitive impairment and dementia. <i>The Cochrane Library</i> , 2021, 2021, CD004034.	1.5	14
22	ESO Guideline on covert cerebral small vessel disease. <i>European Stroke Journal</i> , 2021, 6, CXI-CLXII.	2.7	68
23	PRESERVE: Randomized Trial of Intensive Versus Standard Blood Pressure Control in Small Vessel Disease. <i>Stroke</i> , 2021, 52, 2484-2493.	1.0	17
24	European Stroke Organisation and European Academy of Neurology joint guidelines on post-stroke cognitive impairment. <i>European Stroke Journal</i> , 2021, 6, I-XXXVIII.	2.7	32
25	European Stroke Organisation and European Academy of Neurology joint guidelines on post-stroke cognitive impairment. <i>European Journal of Neurology</i> , 2021, 28, 3883-3920.	1.7	66
27	Regulation of cerebral blood flow in humans: physiology and clinical implications of autoregulation. <i>Physiological Reviews</i> , 2021, 101, 1487-1559.	13.1	303
28	Clinical management of cerebral small vessel disease: a call for a holistic approach. <i>Chinese Medical Journal</i> , 2021, 134, 127-142.	0.9	13
30	Cognitive and balance impairments in people with incidental white matter hyperintensities. <i>Egyptian Journal of Neurology, Psychiatry and Neurosurgery</i> , 2020, 56, .	0.4	1
31	Sporadic cerebral non-amyloid microangiopathy: pathogenesis, diagnosis, and features of treatment policy. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2018, 10, 13-22.	0.2	7
32	Cerebral small vessel disease: classification, clinical manifestations, diagnosis, and features of treatment. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2019, 11, 4-17.	0.2	14
33	Management of Hypertension. <i>Nephrology Self-assessment Program: NephSAP</i> , 2020, 19, 20-31.	3.0	0
34	Sex Differences in Cerebral Small Vessel Disease: A Systematic Review and Meta-Analysis. <i>Frontiers in Neurology</i> , 2021, 12, 756887.	1.1	29
35	Associations of Early Systolic Blood Pressure Control and Outcome After Thrombolysis-Eligible Acute Ischemic Stroke: Results From the ENCHANTED Study. <i>Stroke</i> , 2022, 53, 779-787.	1.0	14
36	Effects of Cilostazol and Isosorbide Mononitrate on Cerebral Hemodynamics in the LACI-1 Randomized Controlled Trial. <i>Stroke</i> , 2022, 53, 29-33.	1.0	10
37	The PASTIS trial: Testing tadalafil for possible use in vascular cognitive impairment. <i>Alzheimer's and Dementia</i> , 2022, 18, 2393-2402.	0.4	18
38	Effect of Antihypertensive Treatment on Cerebral Blood Flow in Older Adults: a Systematic Review and Meta-Analysis. <i>Hypertension</i> , 2022, 79, 1067-1078.	1.3	19

#	ARTICLE	IF	CITATIONS
39	Association of Intensive vs Standard Blood Pressure Control With Cerebral Blood Flow. <i>JAMA Neurology</i> , 2022, 79, 380.	4.5	26
40	New Insights Into Cerebrovascular Pathophysiology and Hypertension. <i>Stroke</i> , 2022, 53, 1054-1064.	1.0	39
41	Aortic Stiffness, Pulse Pressure, and Cerebral Pulsatility Progress Despite Best Medical Management: The OXVASC Cohort. <i>Stroke</i> , 2022, 53, 1310-1317.	1.0	13
42	Impaired dynamic cerebral autoregulation is associated with the severity of neuroimaging features of cerebral small vessel disease. <i>CNS Neuroscience and Therapeutics</i> , 2022, 28, 298-306.	1.9	16
43	Contrast-agent-free state-of-the-art MRI on cerebral small vessel disease”part 1. ASL, IVIM, and CVR. <i>NMR in Biomedicine</i> , 2022, 35, e4742.	1.6	6
44	Application Value of Serum Hcy, TLR4, and CRP in the Diagnosis of Cerebral Small Vessel Disease. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-5.	0.5	2
45	2021 Taiwan Stroke Society Guidelines of blood pressure control for ischemic stroke prevention. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 651-664.	0.6	6
46	Daily blood pressure profile and blood-brain barrier permeability in patients with cerebral small vessel disease. <i>Scientific Reports</i> , 2022, 12, 7723.	1.6	6
47	Cerebral small vessel disease alters neurovascular unit regulation of microcirculation integrity involved in vascular cognitive impairment. <i>Neurobiology of Disease</i> , 2022, 170, 105750.	2.1	24
48	Provisional Decision-Making for Perioperative Blood Pressure Management: A Narrative Review. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-17.	1.9	6
50	Framework for Clinical Trials in Cerebral Small Vessel Disease (FINESSE). <i>JAMA Neurology</i> , 2022, 79, 1187.	4.5	25
51	Influence of Baseline Diastolic Blood Pressure on the Effects of Systolic Blood Pressure Lowering on Cognitive Function in Type 2 Diabetes Mellitus. <i>American Journal of Hypertension</i> , 2023, 36, 120-125.	1.0	1
52	Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	6
53	Controlled arterial hypertension and blood-brain barrier damage in patients with age-related cerebral small vessel disease and cognitive impairments. <i>Zhurnal Nevrologii I Psikhiiatrii Imeni S S Korsakova</i> , 2022, 122, 74.	0.1	0
54	Risk factors related to early neurological deterioration in lacunar stroke and its influence on functional outcome. <i>International Journal of Stroke</i> , 2023, 18, 681-688.	2.9	7
55	The Effects of Amlodipine and other Blood Pressure Lowering Agents on Microvascular Function in Small Vessel Diseases (TREAT-SVDs) trial: Study protocol for a randomised crossover trial. <i>European Stroke Journal</i> , 2023, 8, 387-397.	2.7	4
56	Cerebral small vessel disease: Recent advances and future directions. <i>International Journal of Stroke</i> , 2023, 18, 4-14.	2.9	61
57	Diastolic Blood Pressure and Intensive Blood Pressure Control on Cognitive Outcomes: Insights From the SPRINT MIND Trial. <i>Hypertension</i> , 2023, 80, 580-589.	1.3	6

#	ARTICLE	IF	CITATIONS
58	Association of Intensive vs Standard Blood Pressure Control With Regional Changes in Cerebral Small Vessel Disease Biomarkers. JAMA Network Open, 2023, 6, e231055.	2.8	6
59	Targeting cerebral small vessel disease to promote healthy aging: Preserving physical and cognitive functions in the elderly. Archives of Gerontology and Geriatrics, 2023, 110, 104982.	1.4	3
60	How often does white matter hyperintensity volume regress in cerebral small vessel disease?. International Journal of Stroke, 2023, 18, 937-947.	2.9	2